Tech Company Financing Transactions
Blueprint Medicines Funding Round
On 3/31/2012, Blueprint Medicines raised $6 million in funding from F-Prime Capital and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
3/31/2012
Transaction Type
Venture Equity
Amount
$5,999,000
Round
Undisclosed
Investors
F-Prime Capital (Stephen Knight)
Third Rock Ventures (Mark Levin)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
45 Sidney St. 200
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffery Albers
Chief Medical Officer
Anthony Boral
Chief Scientific Officer
Marion Dorsch
Executive Vice President
Christoph Lengauer
VP - Bus. Development
Kate Haviland
VP - Finance
Michael Landsittel
VP - General Counsel
Tracey McCain
VP - Human Resources
Debbie Durso-Bumpus
VP - Operations
Christopher Murray
Browse more venture capital transactions:
Prev: 3/31/2012: Callisto.fm venture capital transaction
Next: 3/31/2012: Kalidex Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs